Salus’ Flow technology enables analyte pre-concentration from broad range of sample types and volumes, directly integrating with LFA tests (e.g., pregnancy or COVID antigen tests) to provide a ~100-fold increase in overall LFA test sensitivity. Importantly, Flow concentration is completely passive, utilizes simple affordable materials, and does not require additional user steps beyond existing sample collection and LFA-based detection. These capabilities offer new and expanded opportunities for LFA-based testing.

ESP represents a family of ultra-fast and ultra-simple technologies for extracting, concentrating, and purifying analytes (e.g., cells, proteins, nucleic acid, virus) from a broad range of sample types (e.g., water, blood, urine, saliva, sewage) without contaminating, diluting, or discarding any of the original sample. ESP technology provides multi-fold reductions in plastic usage, time, and complexity; providing affordable and streamlined solutions to long-standing challenges of sample preparation for diagnostics and research.

Salus maintains a strong presence in both academic research and industry, providing unique opportunities for collaboration that integrate the development of fundamentally novel technologies with impactful and emerging applications in industry and the health sciences.